From the American Cancer Society:
- Talc is mined from the earth. In this natural form, some talc contains asbestos, a substance known to cause cancers in and around the lungs when inhaled.
- In 1976, the Cosmetic, Toiletry, and Fragrances Association (CTFA), the trade association representing the cosmetic and personal care products industry, issued voluntary guidelines stating that all talc used in cosmetic products in the United States should be free from detectable amounts of asbestos according to their standards.
Dynarex Corporation Expands Recall to Include Additional Products Due to Possible Health Risk
Summary
Company Announcement Date: October 28, 2024
FDA Publish Date: October 28, 2024
Product Type: Food & Beverages
Reason for Announcement: Potential Metal or Chemical Contaminant
Company Name: Dynarex Corporation
Brand Name: dynacare
Product Description: Baby Powder
Company Announcement
Montvale, NJ, October 28, 2024 — Dynarex CorporationExternal Link Disclaimer is expanding the recall initiated on September 19, 2024External Link Disclaimer, to include an additional 373 cases of item number 4875, Dynacare Baby Powder, 14 oz., as well as 647 cases of item number 4874, Dynacare Baby Powder, 4 oz., because they have the potential to be contaminated with asbestos. Asbestos is a naturally occurring mineral that is often found near talc, an ingredient in many cosmetic products. Asbestos, however, is a known carcinogen and its health risks are well-documented. If talc mining sites are not carefully chosen or if proper steps are not taken to adequately purify the talc ore, it may contain asbestos.
The product was sent to distributors on or after January 18, 2024, by direct delivery in the following states: AL, AR, AZ, CA, CO, DE, FL, GA, IA, IL, IN, KY, LA, MA, MD, MN, MO, MS, MT, NC, NE, NJ, NM, NY, OH, OK, OR, PA, TN, TX, UT, VA, VT, WA, WI and sold online on Amazon (Amazon.com).
Both the 4875 and 4874 Baby Powder products are packaged in plastic bottles, 24 bottles to a case for the 14 oz. and 48 to a case for the 4 oz., with lot/batch numbers located on the bottom of the bottle and on each case (see images below).
There have been no illnesses or adverse events reported to date.
The recall was the result of a routine sampling program by the FDA, which revealed that the finished products contained asbestos. Upon further investigation, we have identified additional lots of products that may contain asbestos due to using the same bulk talc material. The company has ceased the distribution of the product as an investigation is proceeding to determine what caused the contamination of the talc.
Consumers who have purchased Dynacare Baby Powder (see products/lots below) should discontinue use immediately and return it for a full refund.
Batch No.
Mfg. Dt.
Exp. Dt.
Pack Size
B 048 31.10.2023 30.10.2026 Baby Powder 14 oz. (397 g)
B 049 01.11.2023 31.10.2026 Baby Powder 14 oz. (397 g)
B 050 02.11.2023 01.11.2026 Baby Powder 14 oz. (397 g)
B 051 29.12.2023 28.12.2026 Baby Powder 14 oz. (397 g)
B 052 30.12.2023 29.12.2026 Baby Powder 14 oz. (397 g)
B 053 01.01.2024 31.12.2026 Baby Powder 4 oz. (113 g)
B 054 03.01.2024 02.01.2027 Baby Powder 4 oz. (113 g)
B 055 04.01.2024 03.01.2027 Baby Powder 4 oz. (113 g)
B 056 05.01.2024 04.01.2027 Baby Powder 4 oz. (113 g)
B 057 06.01.2024 05.01.2027 Baby Powder 4 oz. (113 g)
B 058 08.01.2024 07.01.2027 Baby Powder 4 oz. (113 g)
B 059 31.01.2024 30.01.2027 Baby Powder 4 oz. (113 g)
B 060 01.02.2024 31.01.2027 Baby Powder 4 oz. (113 g)
Please contact Dynarex Corporation at 888-396-2739 or 845-365-8200 during business hours of 8:30 AM to 5:00 PM Eastern Standard Time, or via email at recall@dynarex.com if you have any questions or need information on how to return the product or receive a full refund.
Health care professionals and consumers are encouraged to report any adverse events to FDA’s MedWatch Adverse Event Reporting program by:
Completing and submitting the report online at MedWatch Online Voluntary Reporting Form
Downloading and completing the form, then submitting it via fax at 1-800-FDA-0178
Link to Original Press Release
No comments:
Post a Comment